Compare Amphastar Pharmaceuticals Inc (AMPH) vs Harmony Gold Mining Co. (HMY) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Harmony Gold Mining (HMY) trades at $15.11, up 0.6% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong 2024 results with $61.38B revenue and $8.59B net income, showing improved margins. Recent earnings have been mixed, beating in Q2 2025 but missing in Q4 2025. A dividend of $0.31 is scheduled for May 2026. Analyst consensus is predominantly Hold (70%), with 10% Buy and 20% Sell ratings.

HMY presents a valuation opportunity with a low P/E of 9.67 and EV/EBITDA of 5.06, supported by robust profitability metrics like 20.06% net margin and 32.32% ROE. However, risks include gold price sensitivity to Fed rate hikes, operational execution in transitioning to gold-copper hybrid model, and bearish technical trends. The stock's outlook balances fundamental strength against macroeconomic and sentiment headwinds.